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The c-erbB-2/HER2 proto-oncogene encodes a receptor-type
tyrosine kinase (Yarden and Ullrich, 1988) corresponding to, but
distinct from, the epidermal growth factor receptor (Coussens
et al, 1985; Yamamoto et al, 1986). The HER2 product consists of
three domains, extracellular, transmembrane and intracellular
domains which has tyrosine kinase activity making the HER2
product autophosphorylated. Appreciable amplification and/or
overexpression of this gene has been demonstrated in a variety of
adenocarcinomas including breast cancer (King et al, 1985;
Slamon et al, 1989). However, the expression of this gene in
normal adult tissues is weak (De Potter et al, 1989; Press et al,
1990). Therefore, the HER2 product is thought to be a useful
target for antibody therapy of cancers overexpressing the HER2
gene.
Several studies of murine monoclonal antibodies (Mabs)
directed against the HER2 product have already been reported to
have in vitro and in vivo anti-tumour effects (Drebin et al, 1985;
Hudziak et al, 1989; Hancock et al, 1991; Stancovski et al, 1991;
Tagliabue et al, 1991; Harwerth et al, 1992; Kasprzyk et al, 1992).
However, human anti-mouse antibody response during therapy
would be a major limitation in the clinical application of such
murine mabs (Schroff et al, 1985; Shawler et al, 1985). Carter and
his colleagues constructed a humanized antibody containing only
the antigen-binding loops from a murine mab against the extracel-
lular domain of the HER2 gene product and human variable region
framework residues plus IgG1 constant domains (Carter et al,
1992). A clinical study of the humanized antibody revealed some
objective responses without antibodies against it (Baselga et al,
1996).
We report here the results of a phase I dose escalation study of
the humanized mab (MKC-454) against the HER2 product in
patients with metastatic breast cancer refractory to conventional
chemotherapeutic agents and positive for this oncogene product.
PATIENTS AND METHODS
Patient eligibility
Patients with metastatic breast cancer refractory to conventional
chemo or endocrine therapies and overexpressing the HER2
product were eligible for this study. Patients were considered
refractory to endocrine therapy if hormone receptors were
negative or tumour growth was noted during treatment with
tamoxifen, and were considered refractory to chemotherapy if
disease progression was noted after treatment with doxorubicin-
containing regimens. All patients had measurable disease,
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Summary We conducted a phase I pharmacokinetic dose escalation study of a recombinant humanized anti-p185HER2 monoclonal antibody
(MKC-454) in 18 patients with metastatic breast cancer refractory to chemotherapy. Three or six patients at each dose level received 1, 2, 4
and 8 mg kg–1 of MKC-454 as 90-min intravenous infusions. The first dose was followed in 3 weeks by nine weekly doses. Target trough
serum concentration has been set at 10 mg ml–1 based on in vitro observations. The mean value of minimum trough serum concentrations at
each dose level were 3.58 ± 0.63, 6.53 ± 5.26, 40.2 ± 7.12 and 87.9 ± 23.5 mg ml–1 respectively. At 2 mg kg–1, although minimum trough serum
concentrations were lower than the target trough concentration with a wide range of variation, trough concentrations increased and exceeded
the target concentration, as administrations were repeated weekly. Finally 2 mg kg–1 was considered to be sufficient to achieve the target
trough concentration by the weekly dosing regimen. One patient receiving 1 mg kg–1 had grade 3 fever, one at the 1 mg kg–1 level had severe
fatigue defined as grade 3, and one at 8 mg kg–1 had severe bone pain of grade 3. No antibodies against MKC-454 were detected in any
patients. Objective tumour responses were observed in two patients; one receiving 4 mg kg–1 had a partial response in lung metastases and
the other receiving 8 mg kg–1 had a complete response in soft tissue metastases. These results indicate that MKC-454 is well tolerated and
effective in patients with refractory metastatic breast cancers overexpressing the HER2 proto-oncogene. Further evaluation of this agent with
2–4 mg kg–1 weekly intravenous infusion is warranted. © 1999 Cancer Research Campaign
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with an Eastern Cooperative Oncology Group (ECOG) perfor-
mance status grade 3 or less. Patients who had chemotherapy
within 4 weeks (6 weeks for mitomycin or nitrosurea) or hormonal
therapy within 2 weeks before study entry were ineligible. Written
informed consent was mandatory before study entry.
The expression of HER2 was determined by immunohistochem-
ical staining of the paraffin-embedded thin sections of the primary
or metastatic tumours using rabbit polyclonal antibodies (DAKO,
Glostrup, Denmark and NICHIREI, Tokyo, Japan) or a murine
monoclonal antibody (Lab Corp, North Carolina, USA) against the
human HER2 product. Tumours were considered to overexpress
HER2 if at least 10% of tumour cells had positive membrane
staining.
Treatment
A recombinant humanized anti-HER2 mAb (trastuzumab, MKC-
454) was constructed by molecular engineering from a murine
mAb recognizing the extracellular domain of the HER2 product
(Carter et al, 1992). The drug was administered intravenously at a
constant infusion rate for 90 min. The starting dose level of MKC-
454 was 1 mg kg–1, and subsequent dose escalations were to 2, 4
and 8 mg kg–1. The first dose was followed in 3 weeks by nine
weekly doses. A minimum of three patients assessable for toxicity
were treated at each dose level. If one of the first three patients
entered at any dose level experienced a dose-limiting toxicity, an
additional three patients were entered at that dose level. Toxicities
were graded according to the JCOG toxicity criteria (Tobinai
et al, 1993). Dose-limiting toxicity was defined as any grade 3 or 4
toxicity.
Pharmacokinetics, determination of antibodies against
the humanized antibody and circulating shed antigen
Serum concentrations of MKC-454 were determined in a receptor
binding assay that detects binding with the extracellular domain of
the HER2 product. The recombinant extracellular domain of the
HER2 product provided from Genentech, Inc. was coated on 96-
well microtitre plates. MKC-454 bound to the coated antigen was
detected by horseradish peroxidase-labelled goat anti-human IgG
Fc. The quantitative limit for MKC-454 in serum samples was
156 ng ml–1. The presence of antibodies against MKC-454 was
determined with a bridging-type titre enzyme-linked immunosor-
bent assay (ELISA). Serum concentrations of circulating extracel-
lular domain of the HER2 product, circulating shed antigen were
measured using an ELISA. A pair of polyclonal antibodies against
extracellular domain of the HER2 product were provided from
Genentech, Inc. The quantitative limit for circulating shed antigen
was 1.54 ng ml–1. Pharmacokinetic parameters of MKC-454 after
first administration were determined for each patient. Maximum
serum concentration (Cmax) was the observed value.
Half-life (t1/2), area under concentration-time curve (AUC0–∞),
distribution volume (V) and serum clearance (CL) were estimated
by non-compartmental model of WinNonlin Standard Japanese
Edition Version 1.1 (Scientific Consulting Inc.). As for the trough
serum levels during the weekly treatment period, minimum and
maximum values were obtained for each patient.
Evaluation of response
All responses were reviewed centrally by an independent extra-
mural evaluation committee. A complete response (CR) was
defined as the complete resolution of all measurable tumours for a
duration of at least 4 weeks. Partial response (PR) was defined as a
³ 50% reduction in the sum of the products of the two longest
perpendicular diameters of all measurable tumours for a duration
of at least 4 weeks, a minimal response (MR) as a ³ 25% but less
than 50% reduction in the sum of the products of the two longest
perpendicular diameters of all tumours, and progressive disease
(PD) as a ³ 25% increase in any measurable lesions or the appear-
ance of any new lesion.
RESULTS
Patient characteristics are listed in Table 1. All patients had
received chemotherapy for metastatic disease and 11 patients had
received two or more regimens. All of the metastatic diseases had
become refractory to anthracycline-containing regimens.
Although hormonal therapy for metastatic disease was also given
to a third of the patients, 11 primary tumours were negative for
oestrogen receptor. Twelve patients had pathological grade III
primary tumours.
Serum concentration-time profiles after first administration are
illustrated in Figure 1 and estimated pharmacokinetic parameters
for each patient are summarized in Table 2. Mean Cmax increased in
good proportion to dose. Mean distribution volume (V) ranging
from 52.1 to 74.3 ml kg, was independent of dose, and approxi-
mated the serum space. Half-life (t1/2) increased from 2.7 days at
1420 Y Tokuda et al
British Journal of Cancer (1999) 81(8), 1419–1425 © 1999 Cancer Research Campaign
Table 1 Patient demographics
Parameter No.
No. of patients 18
Age median (years) (range) 51 (32–64)
Performance score (ECOG)
01 0
17
21
Receptor status
Oestrogen receptor
Positive 3
Negative 11
Unknown 4
Progesterone receptor
Positive 3
Negative 10
Unknown 5
Histological grade
II 3
III 12
Unknown 3
Prior treatment
Chemotherapy
Adjuvant chemotherapy 12
Neoadjuvant chemotherapy 1
Metastatic disease (no. of regimens)
17
27
>2 4
Median (range) 2 (1–4)
Hormonal therapy
Adjuvant therapy 11
Metastatic disease 6the lowest dose (1 mg kg–1) to 10.4 days at the highest dose
(8 mg kg–1). Mean serum clearance (CL) decreased dose-depen-
dently from 14.1 to 5.6 ml day–1 kg–1. Trough serum concentrations
during repeated administration of MKC-454 are individually
summarized in Figure 2. Maximum values of trough serum
concentrations at each dose level were 9.19 ± 2.26, 19.1 ± 15.1,
102 ± 47.9, and 248 ± 64.4 mg ml–1 respectively. The mean value
of minimum trough serum concentrations at each dose level were
3.58 ± 0.63, 6.53 ± 5.26, 40.2 ± 7.12 and 87.9 ± 23.5 mg ml–1
respectively. Figure 3 shows the serum concentrations of circu-
lating extracellular domain of the HER2 product, shed antigen.
One patient (Patient No. 3–108) at 2 mg kg–1 with high values of
circulating shed antigen showed reduced values of the trough
serum concentrations compared with those of the other two
Phase I and pharmacokinetic study of anti-HER2 antibody 1421
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Figure 1 Serum concentration-time profiles of MKC-454 after first
administration. The values of serum concentration at a dose level of
1 mg kg–1 (open circle), 2 mg kg–1 (closed circle), 4 mg kg–1 (open triangle),
or 8 mg kg–1 (closed triangle) represent mean ± s.d.
Table 2 Single dose pharmacokinetic parameters of MKC-454 in each patient
Dose Patient no. Cmax t1/2 AUC0–∞ VC L
(mg kg–1) (ng ml–1) (day) (mg day ml–1) (ml kg–1) (ml day kg–1)
1 1–102 17 506 2.6 67 56.0 15.0
1–103a 14 994 2.3 47 45.2 14.2
1–104 21 664 2.4 70 49.6 14.2
1–105 22 230 3.2 94 48.0 10.6
1–106 18 590 2.8 85 45.9 11.8
3–107 15 770 2.3 53 61.1 18.9
Meanb 19 152 2.7 74 52.1 14.1
s.d.b 2 750 0.4 16 6.3 3.2
2 3–108 52 370 1.6 158 33.4 12.7
2–109 42 500 2.3 198 49.1 10.1
1–110 35 270 5.3 190 75.4 10.5
Mean 43 413 3.1 182 52.6 11.1
s.d. 8 537 2.0 21 21.2 1.4
4 3–111 62 340 10.2 549 85.9 7.3
3–112 62 720 7.7 611 77.0 6.5
1–113 92 320 8.4 746 60.0 5.4
Mean 72 460 8.8 635 74.3 6.4
s.d. 17 200 1.3 101 13.2 1.0
8 3–114 167 600 6.4 928 68.8 8.6
1–115 193 500 15.4 2101 77.1 3.8
1–116 197 050 10.3 1954 56.9 4.1
2–117 149 850 10.2 1551 72.4 5.2
3–118 176 700 11.3 1810 67.5 4.4
3–119 133 250 9.0 1111 79.5 7.2
Mean 169 658 10.4 1576 70.4 5.6
s.d. 24 862 3.0 471 8.1 1.9
a0.67 mg/kg of dose was used for calculation of pharmacokinetic parameters because infusion was discontinued at 60 min.
bPatient no. 1–103 was deleted from calculation of mean and s.d. due to different dose.
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Figure 2 Trough serum concentrations of MKC-454. Left and right ends of
each horizontal bar represent minimum and maximum trough serum
concentration of MKC-454 during weekly administrationpatients at the same dose level. Antibodies against MKC-454 were
not detected in any patient.
From a total of 134 administrations of MKC-454, drug-related
toxicity is shown in Table 3. A 38°C or higher fever was observed
in six patients. One patient at 1 mg kg–1 experienced grade 3 fever
up to 40.7°C while receiving the first administration. Despite the
temporary event, further treatment with MKC-454 was not given.
Although one patient had no bone metastasis, the patient at the
dose of 8 mg kg–1 experienced severe generalized bone pain
judged as grade 3. Although the pain subsided within 8 h, adminis-
tration of MKC-454 was discontinued.
After the clinical trial had been completed, treatment responses
of all the 18 patients were assessed by the committee confirming
toxicity and efficacy. Data are summarized in Table 4. Although
no response was observed at the dose level of 1 mg kg–1, one
patient with cervical and mediastinal lymph node metastases had a
MR at the dose level of 2 mg kg–1. One patient with multiple lung
metastases had a PR at 4 mg kg–1. Due to her good response to
date, she has received continuous weekly administration of MKC-
454 4 mg kg–1 for 18 months (Figure 4). A patient at 8 mg kg–1
with skin and bilateral supraclavicular lymph node metastases had
a CR for 3 months (Figure 5). However, skin metastasis relapsed
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Table 3 Toxicity of MKC-454
Dose Dose Dose Dose
1 mg kg–1 2 mg kg–1 4 mg kg–1 8 mg kg–1
n = 6 n = 3 n = 3 n = 6
Grade Grade Grade Grade
I II III I II III I II III I II III
Fever – 2 1 –1–11––1–
Nausea/vomiting – 1 – –––1–––1–
Gastrointestinal disorder – – 1 –––––––––
Liver
A S A T 4––––––1–1––
A L A T 2––––––1––––
Tachycardia – – – ––––1–1––
Rigors 1 – – 1––––––––
Feeling of warmth 1 – – 1––––––––
Bone pain – – – ––––––––1
Tumour pain – – – –––––––1–
Cough – – – 1––––––––
Oedema – – – 1––––––––
Malaise – – – 1––––––––
100
1-102
1-103
1-104
1-105
1-106
3-107
3-108
2-109
1-110
3-111
3-112
1-113
3-114
1-115
1-116
2-117
3-118
3-119
mean
Serum concentration of HER2 ECD (ng ml–1)
Level 1
(1 mg kg
–1)
Level 2
(2 mg kg–1)
Level 3
(4 mg kg
–1)
Level 4
(8 mg kg
–1)
0 200 300 400 500
Figure 3 Serum concentrations of circulating extracellular domain of HER2
product (HER2 ECD). Open circles represent concentrations of HER2 ECD
prior to the commencement of the treatment. Left and right ends of each
horizontal bar represent minimum and maximum concentrations of circulating
HER2 ECD during weekly administration
A
B
Figure 4 Metastatic tumours in the lung before treatment with MKC-454 (A)
and 7 months later showing marked response (B)during the course of the treatment. It is of some interest that the
relapsed tumour cells were still strongly overexpressing the HER2
product. Her circulating shed antigen had been found low through
the entire treatment course. Therefore it was considered that the
circulating shed antigen had not affected her MKC-454 pharmaco-
kinetics.
DISCUSSION
The HER2 product is thought to be a unique and useful target for
antibody therapy of cancers overexpressing the HER gene. Several
series of murine mAbs directed against the extracellular domain of
the HER2 gene product have been developed and examined to
reveal their anti-tumour effects, mainly in vitro. However, human
anti-mouse antibody response during the therapy would be a major
limitation on the clinical application of such murine mAbs.
Preclinical studies suggested that a humanized antibody would
have the same or greater anti-tumour potency in clinical trials than
its murine counterpart (Tokuda et al, 1996). Therefore, a human-
ized antibody against the HER2 gene product is expected to be
useful in the clinic.
Baselga and his colleagues reported the first clinical evidence of
the anti-tumour activity of a humanized antibody against the
HER2 product (Baselga et al, 1996). They set 10 mg ml–1 as the
target trough serum concentration based on in vitro data (Carter
et al, 1992). Our preclinical data also indicated 10 mg ml–1 as a
minimally effective concentration for anti-proliferation effects and
antibody-dependent cell-mediated cytotoxicity (ADCC) (Tokuda
et al, 1996). The dosage and schedule of the antibody administra-
tion in this clinical trial was based on unpublished phase I trials in
the United States. In this clinical trial, non-linear pharmacokinetics
of MCK-454 was demonstrated as previously described for other
monoclonal antibodies (Koizumi et al, 1986; Eger et al, 1987).
According to our data, 4 mg kg–1 is sufficient to achieve the target
Phase I and pharmacokinetic study of anti-HER2 antibody 1423
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Figure 5 Skin metastasis before treatment with MKC-454 (A) showing strong positivity for HER2 product (B) and 4 months later showing pathologically
complete response (C). Relapsing tumour cells with positive HER2 product (D)
Table 4 Response to MKC-454
Dose
mg kg–1 NE PD NC MR PR CR Total
11 4 1 – – – 6
2– 2 – 1 – – 3
4– 2 – – 1 – 3
81 1 1 2 – 1 6
Total 2 9 2 3 1 1 18
NE, not evaluable; PD, progressive disease; NC, no change; MR, minimal
response; PR, partial response; CR, complete response.trough serum concentration (10 mg ml–1). At 2 mg kg–1, although
minimum trough serum concentrations were lower than the target
concentration with a wide range of variation, trough serum
concentrations increased and exceeded the target concentration in
the case of patients with absent or low circulating shed antigen
(Patient nos 2–109 and 1–110), as administrations were repeated
weekly. The maximum trough serum concentration of patient nos
2–109 and 1–110 were 35.4 and 16.7 mg ml–1 respectively.
Although 16.7 mg ml–1 was lower due to discontinuation of treat-
ment before reaching steady state, these values corresponded to
54 ± 32 mg ml–1 observed in the previous clinical trial (Pegram
et al, 1998) which used 100 mg per body as weekly dose level.
These suggested that 2 mg kg–1 was also sufficient to achieve the
target concentration by the weekly dosing regimen. A patient with
high circulating shed antigen at 2 mg kg–1 (Patient no. 3–108)
showed reduced serum concentrations. This observation was
consistent with previous reports suggesting that high circulating
shed antigen decrease the half-life and the trough serum concen-
trations of humanized mAb against HER2 product (Baselga et al,
1996; Pegram et al, 1998). Therefore, monitoring of circulating
shed antigen level is considered to be essential in MKC-454
therapy and more than 2 mg kg–1 may be necessary in patients with
high circulating shed antigen.
Responding cases, including MRs, were observed at the dose
levels of 2 mg kg–1 or more. One patient with a PR for lung
metastases who relapsed after high-dose chemotherapy received
4 mg kg–1 of MKC-454. The other responding patient receiving
8 mg kg–1 achieved a CR for skin metastases, which had been
heavily treated with chemotherapy and radiotherapy. Despite
continuous treatment of MKC-454, it is noteworthy that the HER2
product was still remarkably overexpressed in tumour cells of
relapsed skin lesions. Circulating shed antigen in this patient had
been low. It is possible that tumour clones overexpressing trun-
cated forms of the extracellular domain of the HER2 product
appeared (Scott et al, 1993), but confirmation of this would require
further analysis.
Toxicity caused by the treatment was well tolerated compared
with that of chemotherapeutic drugs. Two patients discontinued
the treatment after the first administration. However, both
toxicities were temporary and could have been prevented with
prophylactic use of drugs such as anti-inflammatory agents, which
was prohibited in the protocol of this study.
In conclusion, MKC-454 showed clinical activity with
minimum toxicity. These findings indicate that this treatment
deserves further clinical trials at suggested weekly intravenous
infusions of 2–4 mg kg–1.
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